ResMed (RMD) is expanding its U.S. footprint with a new distribution center in Greenwood, Indiana, planned to begin operations in 2027. The facility aims to widen North American coverage for its sleep and respiratory care products.

ResMed’s new Greenwood distribution hub comes as the stock has eased slightly in the short term, with a 7 day share price return showing a 1.74% decline, while longer term performance looks steadier, including a 1 year total shareholder return of 10.92% and a 5 year total shareholder return of 49.08%.

If this logistics expansion has you thinking about how healthcare and technology intersect, it could be a good time to check out 28 healthcare AI stocks as another way to source ideas in this space.

With ResMed shares easing in the short term but showing stronger multi year total returns, along with an indicated discount to both analyst targets and intrinsic value estimates, is this a genuine buying opportunity, or is the market already pricing in future growth?

Most Popular Narrative: 13.9% Undervalued

ResMed's most followed narrative pegs fair value at $297.47, above the last close of $256.26, framing the stock as modestly undervalued on that view.

Optimization initiatives in procurement, manufacturing, and logistics, along with the build out of the U.S. manufacturing footprint, are structurally improving gross margins. When combined with operating leverage from global scale, these factors are expected to boost overall earnings and free cash flow.

Curious what kind of revenue run rate, margin profile, and future earnings power this fair value leans on, and how tightly analysts cluster around those assumptions.

Result: Fair Value of $297.47 (UNDERVALUED)

However, this fair value view could be challenged if reimbursement pressure hits device pricing or if alternative sleep apnea therapies start to cap demand for ResMed’s hardware.

Next Steps

If this mix of potential upside and risks leaves you on the fence, it makes sense to move quickly and test the numbers yourself, starting with 4 key rewards.

Looking for more investment ideas?

If ResMed is on your radar, do not stop here; broaden your watchlist with focused sets of stocks that match the kind of portfolio you want to build.

• Target potential mispricings by scanning our list of 49 high quality undervalued stocks that combine quality fundamentals with prices that may not fully reflect their underlying strength.
• Prioritize steadier profiles by reviewing 76 resilient stocks with low risk scores, highlighting companies that score well on factors linked to resilience and lower overall risk.
• Hunt for early opportunities with screener containing 24 high quality undiscovered gems, a collection of under the radar names that still show solid financial traits.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.